Details of Drug Off-Target (DOT)

General Information of Drug Off-Target (DOT) (ID: OTCQJAB0)

• DOT Name: Baculoviral IAP repeat-containing protein 6 (BIRC6)
• Synonyms: EC 2.3.2.27; BIR repeat-containing ubiquitin-conjugating enzyme; BRUCE; RING-type E3 ubiquitin transferase BIRC6; Ubiquitin-conjugating BIR domain enzyme apollon; APOLLON
• Gene Name: BIRC6
• Related Disease:
  Acute myelogenous leukaemia
  Prostate cancer
  Prostate carcinoma
  Acute leukaemia
  Acute lymphocytic leukaemia
  Acute monocytic leukemia
  Advanced cancer
  B-cell neoplasm
  Benign neoplasm
  Bone osteosarcoma
  Brain cancer
  Breast cancer
  Breast carcinoma
  Carcinoma of liver and intrahepatic biliary tract
  Cardiac failure
  Castration-resistant prostate carcinoma
  Childhood acute lymphoblastic leukemia
  Colon cancer
  Colon carcinoma
  Colorectal carcinoma
  Congestive heart failure
  Epithelial ovarian cancer
  Esophageal squamous cell carcinoma
  Glaucoma/ocular hypertension
  Liver cancer
  Lung cancer
  Lung squamous cell carcinoma
  Melanoma
  Non-small-cell lung cancer
  Osteosarcoma
  Ovarian cancer
  Ovarian neoplasm
  Adult glioblastoma
  Glioblastoma multiforme
  Angle-closure glaucoma
  Polycystic kidney disease
  Primary angle-closure glaucoma
  Hepatocellular carcinoma
  Neoplasm
  Neuroblastoma
  Parathyroid gland carcinoma
• UniProt ID: BIRC6_HUMAN
• PDB ID: 3CEG; 8ATM; 8ATO; 8ATU; 8ATX; 8AUK; 8AUW; 8E2D; 8E2E; 8E2F; 8E2G; 8E2H; 8E2I; 8E2K
• EC Number: 2.3.2.27
• Pfam ID: PF00653 ; PF12356 ; PF00179
• Sequence:
  MVTGGGAAPPGTVTEPLPSVIVLSAGRKMAAAAAAASGPGCSSAAGAGAAGVSEWLVLRD
  GCMHCDADGLHSLSYHPALNAILAVTSRGTIKVIDGTSGATLQASALSAKPGGQVKCQYI
  SAVDKVIFVDDYAVGCRKDLNGILLLDTALQTPVSKQDDVVQLELPVTEAQQLLSACLEK
  VDISSTEGYDLFITQLKDGLKNTSHETAANHKVAKWATVTFHLPHHVLKSIASAIVNELK
  KINQNVAALPVASSVMDRLSYLLPSARPELGVGPGRSVDRSLMYSEANRRETFTSWPHVG
  YRWAQPDPMAQAGFYHQPASSGDDRAMCFTCSVCLVCWEPTDEPWSEHERHSPNCPFVKG
  EHTQNVPLSVTLATSPAQFPCTDGTDRISCFGSGSCPHFLAAATKRGKICIWDVSKLMKV
  HLKFEINAYDPAIVQQLILSGDPSSGVDSRRPTLAWLEDSSSCSDIPKLEGDSDDLLEDS
  DSEEHSRSDSVTGHTSQKEAMEVSLDITALSILQQPEKLQWEIVANVLEDTVKDLEELGA
  NPCLTNSKSEKTKEKHQEQHNIPFPCLLAGGLLTYKSPATSPISSNSHRSLDGLSRTQGE
  SISEQGSTDNESCTNSELNSPLVRRTLPVLLLYSIKESDEKAGKIFSQMNNIMSKSLHDD
  GFTVPQIIEMELDSQEQLLLQDPPVTYIQQFADAAANLTSPDSEKWNSVFPKPGTLVQCL
  RLPKFAEEENLCIDSITPCADGIHLLVGLRTCPVESLSAINQVEALNNLNKLNSALCNRR
  KGELESNLAVVNGANISVIQHESPADVQTPLIIQPEQRNVSGGYLVLYKMNYATRIVTLE
  EEPIKIQHIKDPQDTITSLILLPPDILDNREDDCEEPIEDMQLTSKNGFEREKTSDISTL
  GHLVITTQGGYVKILDLSNFEILAKVEPPKKEGTEEQDTFVSVIYCSGTDRLCACTKGGE
  LHFLQIGGTCDDIDEADILVDGSLSKGIEPSSEGSKPLSNPSSPGISGVDLLVDQPFTLE
  ILTSLVELTRFETLTPRFSATVPPCWVEVQQEQQQRRHPQHLHQQHHGDAAQHTRTWKLQ
  TDSNSWDEHVFELVLPKACMVGHVDFKFVLNSNITNIPQIQVTLLKNKAPGLGKVNALNI
  EVEQNGKPSLVDLNEEMQHMDVEESQCLRLCPFLEDHKEDILCGPVWLASGLDLSGHAGM
  LTLTSPKLVKGMAGGKYRSFLIHVKAVNERGTEEICNGGMRPVVRLPSLKHQSNKGYSLA
  SLLAKVAAGKEKSSNVKNENTSGTRKSENLRGCDLLQEVSVTIRRFKKTSISKERVQRCA
  MLQFSEFHEKLLNTLCRKTDDGQITEHAQSLVLDTLCWLAGVHSNGPGSSKEGNENLLSK
  TRKFLSDIVRVCFFEAGRSIAHKCARFLALCISNGKCDPCQPAFGPVLLKALLDNMSFLP
  AATTGGSVYWYFVLLNYVKDEDLAGCSTACASLLTAVSRQLQDRLTPMEALLQTRYGLYS
  SPFDPVLFDLEMSGSSCKNVYNSSIGVQSDEIDLSDVLSGNGKVSSCTAAEGSFTSLTGL
  LEVEPLHFTCVSTSDGTRIERDDAMSSFGVTPAVGGLSSGTVGEASTALSSAAQVALQSL
  SHAMASAEQQLQVLQEKQQQLLKLQQQKAKLEAKLHQTTAAAAAAASAVGPVHNSVPSNP
  VAAPGFFIHPSDVIPPTPKTTPLFMTPPLTPPNEAVSVVINAELAQLFPGSVIDPPAVNL
  AAHNKNSNKSRMNPLGSGLALAISHASHFLQPPPHQSIIIERMHSGARRFVTLDFGRPIL
  LTDVLIPTCGDLASLSIDIWTLGEEVDGRRLVVATDISTHSLILHDLIPPPVCRFMKITV
  IGRYGSTNARAKIPLGFYYGHTYILPWESELKLMHDPLKGEGESANQPEIDQHLAMMVAL
  QEDIQCRYNLACHRLETLLQSIDLPPLNSANNAQYFLRKPDKAVEEDSRVFSAYQDCIQL
  QLQLNLAHNAVQRLKVALGASRKMLSETSNPEDLIQTSSTEQLRTIIRYLLDTLLSLLHA
  SNGHSVPAVLQSTFHAQACEELFKHLCISGTPKIRLHTGLLLVQLCGGERWWGQFLSNVL
  QELYNSEQLLIFPQDRVFMLLSCIGQRSLSNSGVLESLLNLLDNLLSPLQPQLPMHRRTE
  GVLDIPMISWVVMLVSRLLDYVATVEDEAAAAKKPLNGNQWSFINNNLHTQSLNRSSKGS
  SSLDRLYSRKIRKQLVHHKQQLNLLKAKQKALVEQMEKEKIQSNKGSSYKLLVEQAKLKQ
  ATSKHFKDLIRLRRTAEWSRSNLDTEVTTAKESPEIEPLPFTLAHERCISVVQKLVLFLL
  SMDFTCHADLLLFVCKVLARIANATRPTIHLCEIVNEPQLERLLLLLVGTDFNRGDISWG
  GAWAQYSLTCMLQDILAGELLAPVAAEAMEEGTVGDDVGATAGDSDDSLQQSSVQLLETI
  DEPLTHDITGAPPLSSLEKDKEIDLELLQDLMEVDIDPLDIDLEKDPLAAKVFKPISSTW
  YDYWGADYGTYNYNPYIGGLGIPVAKPPANTEKNGSQTVSVSVSQALDARLEVGLEQQAE
  LMLKMMSTLEADSILQALTNTSPTLSQSPTGTDDSLLGGLQAANQTSQLIIQLSSVPMLN
  VCFNKLFSMLQVHHVQLESLLQLWLTLSLNSSSTGNKENGADIFLYNANRIPVISLNQAS
  ITSFLTVLAWYPNTLLRTWCLVLHSLTLMTNMQLNSGSSSAIGTQESTAHLLVSDPNLIH
  VLVKFLSGTSPHGTNQHSPQVGPTATQAMQEFLTRLQVHLSSTCPQIFSEFLLKLIHILS
  TERGAFQTGQGPLDAQVKLLEFTLEQNFEVVSVSTISAVIESVTFLVHHYITCSDKVMSR
  SGSDSSVGARACFGGLFANLIRPGDAKAVCGEMTRDQLMFDLLKLVNILVQLPLSGNREY
  SARVSVTTNTTDSVSDEEKVSGGKDGNGSSTSVQGSPAYVADLVLANQQIMSQILSALGL
  CNSSAMAMIIGASGLHLTKHENFHGGLDAISVGDGLFTILTTLSKKASTVHMMLQPILTY
  MACGYMGRQGSLATCQLSEPLLWFILRVLDTSDALKAFHDMGGVQLICNNMVTSTRAIVN
  TARSMVSTIMKFLDSGPNKAVDSTLKTRILASEPDNAEGIHNFAPLGTITSSSPTAQPAE
  VLLQATPPHRRARSAAWSYIFLPEEAWCDLTIHLPAAVLLKEIHIQPHLASLATCPSSVS
  VEVSADGVNMLPLSTPVVTSGLTYIKIQLVKAEVASAVCLRLHRPRDASTLGLSQIKLLG
  LTAFGTTSSATVNNPFLPSEDQVSKTSIGWLRLLHHCLTHISDLEGMMASAAAPTANLLQ
  TCAALLMSPYCGMHSPNIEVVLVKIGLQSTRIGLKLIDILLRNCAASGSDPTDLNSPLLF
  GRLNGLSSDSTIDILYQLGTTQDPGTKDRIQALLKWVSDSARVAAMKRSGRMNYMCPNSS
  TVEYGLLMPSPSHLHCVAAILWHSYELLVEYDLPALLDQELFELLFNWSMSLPCNMVLKK
  AVDSLLCSMCHVHPNYFSLLMGWMGITPPPVQCHHRLSMTDDSKKQDLSSSLTDDSKNAQ
  APLALTESHLATLASSSQSPEAIKQLLDSGLPSLLVRSLASFCFSHISSSESIAQSIDIS
  QDKLRRHHVPQQCNKMPITADLVAPILRFLTEVGNSHIMKDWLGGSEVNPLWTALLFLLC
  HSGSTSGSHNLGAQQTSARSASLSSAATTGLTTQQRTAIENATVAFFLQCISCHPNNQKL
  MAQVLCELFQTSPQRGNLPTSGNISGFIRRLFLQLMLEDEKVTMFLQSPCPLYKGRINAT
  SHVIQHPMYGAGHKFRTLHLPVSTTLSDVLDRVSDTPSITAKLISEQKDDKEKKNHEEKE
  KVKAENGFQDNYSVVVASGLKSQSKRAVSATPPRPPSRRGRTIPDKIGSTSGAEAANKII
  TVPVFHLFHKLLAGQPLPAEMTLAQLLTLLYDRKLPQGYRSIDLTVKLGSRVITDPSLSK
  TDSYKRLHPEKDHGDLLASCPEDEALTPGDECMDGILDESLLETCPIQSPLQVFAGMGGL
  ALIAERLPMLYPEVIQQVSAPVVTSTTQEKPKDSDQFEWVTIEQSGELVYEAPETVAAEP
  PPIKSAVQTMSPIPAHSLAAFGLFLRLPGYAEVLLKERKHAQCLLRLVLGVTDDGEGSHI
  LQSPSANVLPTLPFHVLRSLFSTTPLTTDDGVLLRRMALEIGALHLILVCLSALSHHSPR
  VPNSSVNQTEPQVSSSHNPTSTEEQQLYWAKGTGFGTGSTASGWDVEQALTKQRLEEEHV
  TCLLQVLASYINPVSSAVNGEAQSSHETRGQNSNALPSVLLELLSQSCLIPAMSSYLRND
  SVLDMARHVPLYRALLELLRAIASCAAMVPLLLPLSTENGEEEEEQSECQTSVGTLLAKM
  KTCVDTYTNRLRSKRENVKTGVKPDASDQEPEGLTLLVPDIQKTAEIVYAATTSLRQANQ
  EKKLGEYSKKAAMKPKPLSVLKSLEEKYVAVMKKLQFDTFEMVSEDEDGKLGFKVNYHYM
  SQVKNANDANSAARARRLAQEAVTLSTSLPLSSSSSVFVRCDEERLDIMKVLITGPADTP
  YANGCFEFDVYFPQDYPSSPPLVNLETTGGHSVRFNPNLYNDGKVCLSILNTWHGRPEEK
  WNPQTSSFLQVLVSVQSLILVAEPYFNEPGYERSRGTPSGTQSSREYDGNIRQATVKWAM
  LEQIRNPSPCFKEVIHKHFYLKRVEIMAQCEEWIADIQQYSSDKRVGRTMSHHAAALKRH
  TAQLREELLKLPCPEGLDPDTDDAPEVCRATTGAEETLMHDQVKPSSSKELPSDFQL
• Function: Anti-apoptotic protein which can regulate cell death by controlling caspases and by acting as an E3 ubiquitin-protein ligase. Has an unusual ubiquitin conjugation system in that it could combine in a single polypeptide, ubiquitin conjugating (E2) with ubiquitin ligase (E3) activity, forming a chimeric E2/E3 ubiquitin ligase. Its targets include CASP9 and DIABLO/SMAC. Acts as an inhibitor of CASP3, CASP7 and CASP9. Important regulator for the final stages of cytokinesis. Crucial for normal vesicle targeting to the site of abscission, but also for the integrity of the midbody and the midbody ring, and its striking ubiquitin modification.
• Tissue Specificity: Expressed in brain cancer cells.
• KEGG Pathway:
  Ubiquitin mediated proteolysis (hsa04120)
  Autophagy - animal (hsa04140)
  Apoptosis - multiple species (hsa04215)
• Reactome Pathway:
  Signaling by ALK fusions and activated point mutants (R-HSA-9725370)
  ALK mutants bind TKIs (R-HSA-9700645)

Molecular Interaction Atlas (MIA) of This DOT

41 Disease(s) Related to This DOT

Disease Name	Disease ID	Evidence Level	Mode of Inheritance	REF
Acute myelogenous leukaemia	DISCSPTN	Definitive	Biomarker	[1]
Prostate cancer	DISF190Y	Definitive	Altered Expression	[2]
Prostate carcinoma	DISMJPLE	Definitive	Altered Expression	[2]
Acute leukaemia	DISDQFDI	Strong	Altered Expression	[3]
Acute lymphocytic leukaemia	DISPX75S	Strong	Altered Expression	[3]
Acute monocytic leukemia	DIS28NEL	Strong	Altered Expression	[3]
Advanced cancer	DISAT1Z9	Strong	Biomarker	[4]
B-cell neoplasm	DISVY326	Strong	Altered Expression	[5]
Benign neoplasm	DISDUXAD	Strong	Biomarker	[6]
Bone osteosarcoma	DIST1004	Strong	Altered Expression	[7]
Brain cancer	DISBKFB7	Strong	Altered Expression	[8]
Breast cancer	DIS7DPX1	Strong	Biomarker	[9]
Breast carcinoma	DIS2UE88	Strong	Biomarker	[9]
Carcinoma of liver and intrahepatic biliary tract	DIS8WA0W	Strong	Biomarker	[10]
Cardiac failure	DISDC067	Strong	Genetic Variation	[11]
Castration-resistant prostate carcinoma	DISVGAE6	Strong	Altered Expression	[12]
Childhood acute lymphoblastic leukemia	DISJ5D6U	Strong	Biomarker	[3]
Colon cancer	DISVC52G	Strong	Biomarker	[13]
Colon carcinoma	DISJYKUO	Strong	Biomarker	[13]
Colorectal carcinoma	DIS5PYL0	Strong	Biomarker	[14]
Congestive heart failure	DIS32MEA	Strong	Genetic Variation	[11]
Epithelial ovarian cancer	DIS56MH2	Strong	Biomarker	[7]
Esophageal squamous cell carcinoma	DIS5N2GV	Strong	Biomarker	[15]
Glaucoma/ocular hypertension	DISLBXBY	Strong	Biomarker	[16]
Liver cancer	DISDE4BI	Strong	Biomarker	[10]
Lung cancer	DISCM4YA	Strong	Altered Expression	[17]
Lung squamous cell carcinoma	DISXPIBD	Strong	Altered Expression	[17]
Melanoma	DIS1RRCY	Strong	Genetic Variation	[18]
Non-small-cell lung cancer	DIS5Y6R9	Strong	Biomarker	[19]
Osteosarcoma	DISLQ7E2	Strong	Altered Expression	[7]
Ovarian cancer	DISZJHAP	Strong	Biomarker	[7]
Ovarian neoplasm	DISEAFTY	Strong	Biomarker	[7]
Adult glioblastoma	DISVP4LU	moderate	Biomarker	[20]
Glioblastoma multiforme	DISK8246	moderate	Biomarker	[20]
Angle-closure glaucoma	DISZ95KY	Disputed	Genetic Variation	[21]
Polycystic kidney disease	DISWS3UY	Disputed	Biomarker	[22]
Primary angle-closure glaucoma	DISX8UKZ	Disputed	Genetic Variation	[21]
Hepatocellular carcinoma	DIS0J828	Limited	Biomarker	[10]
Neoplasm	DISZKGEW	Limited	Altered Expression	[14]
Neuroblastoma	DISVZBI4	Limited	Biomarker	[23]
Parathyroid gland carcinoma	DISEER2W	Limited	Altered Expression	[24]

This DOT Affected the Drug Response of 2 Drug(s)

Drug Name	Drug ID	Highest Status	Interaction	REF
Fluorouracil	DMUM7HZ	Approved	Baculoviral IAP repeat-containing protein 6 (BIRC6) decreases the response to substance of Fluorouracil.	[37]
Epirubicin	DMPDW6T	Approved	Baculoviral IAP repeat-containing protein 6 (BIRC6) decreases the response to substance of Epirubicin.	[37]

10 Drug(s) Affected the Gene/Protein Processing of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
Acetaminophen	DMUIE76	Approved	Acetaminophen decreases the expression of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[25]
Doxorubicin	DMVP5YE	Approved	Doxorubicin increases the expression of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[26]
Cupric Sulfate	DMP0NFQ	Approved	Cupric Sulfate increases the expression of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[27]
Cisplatin	DMRHGI9	Approved	Cisplatin decreases the expression of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[28]
Estradiol	DMUNTE3	Approved	Estradiol increases the expression of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[29]
Ivermectin	DMDBX5F	Approved	Ivermectin decreases the expression of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[30]
Zoledronate	DMIXC7G	Approved	Zoledronate decreases the expression of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[31]
Benzo(a)pyrene	DMN7J43	Phase 1	Benzo(a)pyrene increases the mutagenesis of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[32]
Formaldehyde	DM7Q6M0	Investigative	Formaldehyde decreases the expression of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[35]
Milchsaure	DM462BT	Investigative	Milchsaure increases the expression of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[36]

2 Drug(s) Affected the Post-Translational Modifications of This DOT

Drug Name	Drug ID	Highest Status	Interaction	REF
PMID28870136-Compound-52	DMFDERP	Patented	PMID28870136-Compound-52 affects the phosphorylation of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[33]
Bisphenol A	DM2ZLD7	Investigative	Bisphenol A decreases the methylation of Baculoviral IAP repeat-containing protein 6 (BIRC6).	[34]

References

• [1] MicroRNA-204 Potentiates the Sensitivity of Acute Myeloid Leukemia Cells to Arsenic Trioxide.Oncol Res. 2019 Sep 23;27(9):1035-1042. doi: 10.3727/096504019X15528367532612. Epub 2019 Apr 8.
• [2] The BIRC6 gene as a novel target for therapy of prostate cancer: dual targeting of inhibitors of apoptosis.Oncotarget. 2014 Aug 30;5(16):6896-908. doi: 10.18632/oncotarget.2229.
• [3] BIRC6/Apollon gene expression in childhood acute leukemia: impact on therapeutic response and prognosis.Eur J Haematol. 2012 Feb;88(2):118-27. doi: 10.1111/j.1600-0609.2011.01734.x. Epub 2012 Jan 4.
• [4] RNA interference-mediated validation of survivin and Apollon/BRUCE as new therapeutic targets for cancer therapy.Curr Top Med Chem. 2012;12(2):69-78. doi: 10.2174/156802612798919169.
• [5] circ-BIRC6, a circular RNA, promotes hepatocellular carcinoma progression by targeting the miR-3918/Bcl2 axis.Cell Cycle. 2019 May;18(9):976-989. doi: 10.1080/15384101.2019.1601477. Epub 2019 Apr 16.
• [6] Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil.Gene Ther. 2008 Apr;15(7):484-94. doi: 10.1038/gt.2008.6. Epub 2008 Jan 31.
• [7] Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.PLoS One. 2019 May 15;14(5):e0216553. doi: 10.1371/journal.pone.0216553. eCollection 2019.
• [8] A human IAP-family gene, apollon, expressed in human brain cancer cells.Biochem Biophys Res Commun. 1999 Nov 2;264(3):847-54. doi: 10.1006/bbrc.1999.1585.
• [9] Apollon gene silencing induces apoptosis in breast cancer cells through p53 stabilisation and caspase-3 activation.Br J Cancer. 2009 Mar 10;100(5):739-46. doi: 10.1038/sj.bjc.6604927. Epub 2009 Feb 17.
• [10] The BRUCE-ATR Signaling Axis Is Required for Accurate DNA Replication and Suppression of Liver Cancer Development.Hepatology. 2019 Jun;69(6):2608-2622. doi: 10.1002/hep.30529. Epub 2019 Mar 13.
• [11] Patients with HFpEF and HFmrEF have different clinical characteristics in Turkey: A multicenter observational study.Eur J Intern Med. 2019 Mar;61:88-95. doi: 10.1016/j.ejim.2018.11.001. Epub 2018 Nov 13.
• [12] BIRC6 Targeting as Potential Therapy for Advanced, Enzalutamide-Resistant Prostate Cancer.Clin Cancer Res. 2017 Mar 15;23(6):1542-1551. doi: 10.1158/1078-0432.CCR-16-0718. Epub 2016 Sep 23.
• [13] Comparative proteomics of colon cancer stem cells and differentiated tumor cells identifies BIRC6 as a potential therapeutic target.Mol Cell Proteomics. 2011 Dec;10(12):M111.011353. doi: 10.1074/mcp.M111.011353. Epub 2011 Jul 25.
• [14] Overexpression of BIRC6 Is a Predictor of Prognosis for Colorectal Cancer.PLoS One. 2015 May 1;10(5):e0125281. doi: 10.1371/journal.pone.0125281. eCollection 2015.
• [15] Apollon modulates chemosensitivity in human esophageal squamous cell carcinoma.Oncotarget. 2014 Aug 30;5(16):7183-97. doi: 10.18632/oncotarget.2293.
• [16] Research progress on human genes involved in the pathogenesis of glaucoma (Review).Mol Med Rep. 2018 Jul;18(1):656-674. doi: 10.3892/mmr.2018.9071. Epub 2018 May 23.
• [17] Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.J Thorac Oncol. 2013 Feb;8(2):161-70. doi: 10.1097/JTO.0b013e31827d5237.
• [18] Role of Apollon in human melanoma resistance to antitumor agents that activate the intrinsic or the extrinsic apoptosis pathways.Clin Cancer Res. 2012 Jun 15;18(12):3316-27. doi: 10.1158/1078-0432.CCR-11-2232. Epub 2012 May 2.
• [19] Diagnostic investigation of BIRC6 and SIRT1 protein expression level as potential prognostic biomarkers in patients with non-small cell lung cancer.Clin Respir J. 2018 Feb;12(2):633-638. doi: 10.1111/crj.12572. Epub 2016 Nov 20.
• [20] miR-30e Blocks Autophagy and Acts Synergistically with Proanthocyanidin for Inhibition of AVEN and BIRC6 to Increase Apoptosis in Glioblastoma Stem Cells and Glioblastoma SNB19 Cells.PLoS One. 2016 Jul 7;11(7):e0158537. doi: 10.1371/journal.pone.0158537. eCollection 2016.
• [21] Association of a polymorphism in the BIRC6 gene with pseudoexfoliative glaucoma.PLoS One. 2014 Aug 13;9(8):e105023. doi: 10.1371/journal.pone.0105023. eCollection 2014.
• [22] Family-based analysis identified CD2 as a susceptibility gene for primary open angle glaucoma in Chinese Han population.J Cell Mol Med. 2014 Apr;18(4):600-9. doi: 10.1111/jcmm.12201. Epub 2014 Mar 6.
• [23] Identification of BIRC6 as a novel intervention target for neuroblastoma therapy.BMC Cancer. 2012 Jul 12;12:285. doi: 10.1186/1471-2407-12-285.
• [24] Molecular profiling of parathyroid hyperplasia, adenoma and carcinoma.Pathol Oncol Res. 2012 Jul;18(3):607-14. doi: 10.1007/s12253-011-9483-7. Epub 2011 Dec 24.
• [25] Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
• [26] Rapid induction of IAP family proteins and Smac/DIABLO expression after proapoptotic stimulation with doxorubicin in RPMI 8226 multiple myeloma cells. Exp Mol Pathol. 2007 Dec;83(3):405-12. doi: 10.1016/j.yexmp.2007.04.001. Epub 2007 Apr 18.
• [27] Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
• [28] Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
• [29] Genistein and bisphenol A exposure cause estrogen receptor 1 to bind thousands of sites in a cell type-specific manner. Genome Res. 2012 Nov;22(11):2153-62.
• [30] Quantitative proteomics reveals a broad-spectrum antiviral property of ivermectin, benefiting for COVID-19 treatment. J Cell Physiol. 2021 Apr;236(4):2959-2975. doi: 10.1002/jcp.30055. Epub 2020 Sep 22.
• [31] Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol. 2009 Mar;144(5):667-76. doi: 10.1111/j.1365-2141.2008.07504.x. Epub 2008 Nov 20.
• [32] Exome-wide mutation profile in benzo[a]pyrene-derived post-stasis and immortal human mammary epithelial cells. Mutat Res Genet Toxicol Environ Mutagen. 2014 Dec;775-776:48-54. doi: 10.1016/j.mrgentox.2014.10.011. Epub 2014 Nov 4.
• [33] Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
• [34] DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
• [35] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.
• [36] Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
• [37] [Knock-down of apollon gene by antisense oligodeoxynucleotide inhibits the proliferation of Lovo cells and enhances chemo-sensitivity]. Yao Xue Xue Bao. 2011 Feb;46(2):138-45.